The first antiseizure medication (ASM) is ineffective or intolerable in 50% of epilepsy cases. Selection between more than 25 available ASMs is guided by epilepsy factors, but also age and comorbidities. Randomized evidence for particular patient subgroups is seldom available. We asked whether register data could be used for retention rate calculations based on demographics, comorbidities, and ASM history, and quantified the potential improvement in retention rates of the first ASM in several large epilepsy cohorts. We also describe retention rates in patients with epilepsy after traumatic brain injury and dementia, patient groups with little available evidence.

中文翻译：

---

通过个性化抗癫痫药物选择提高保留率的潜力：基于注册的分析

第一种抗癫痫药物 (ASM) 在 50% 的癫痫病例中无效或无法耐受。超过 25 种可用的 ASM 之间的选择受癫痫因素、年龄和合并症的指导。很少有针对特定患者亚组的随机证据。我们询问登记数据是否可用于基于人口统计、合并症和 ASM 历史的保留率计算，并量化了几个大型癫痫队列中第一个 ASM 保留率的潜在改善。我们还描述了创伤性脑损伤和痴呆后癫痫患者的保留率，这些患者群体几乎没有可用的证据。